Cor Vasa 2026, 68(2):161-165 | DOI: 10.33678/cor.2025.100

Coronary Flow Velocity Reserve in Subjects with High HDL Cholesterol

Ozge Telci Caklilia, Fatma Betul Ozcanb, Ramazan Cakmakc, Tugce Irgib, Oguz Konalb, Mustafa Caliskanb
a Department of Endocrinology and Metabolism, Kocaeli City Hospital, Kocaeli, Turkey
b Cardiology, Medeniyet University, Istanbul, Turkey
c Department of Endocrinology and Metabolism, Medical Park Hospital, Istanbul, Turkey

Background: In recent years, it has been debated whether high HDL-C definitely provides cardiovascular protection. We compared coronary flow velocity reserve (CFVR) of subjects with normal HDL-C levels with subjects who have high HDL-C levels.

Methods and results: Subjects who were evaluated for angina with no pathological findings at the Cardiology Department of Istanbul Medeniyet University between 2012–2022 were screened and included to analysis if their HDL-C levels were ≥ 50 mg/dL. They were divided into two groups: (1) patients with HDL-C ≥ 70 mg/dL and (2) patients with HDL-C ≥ 50 and < 70 mg/ dL. Groups were compared in terms of CFVR.

Results: A total of 121 subjects (mean age: 37.60 ± 9.23; male n = 46, 38%) were included. There were 9 (7.4%) participants with HDL-C levels ≥ 70 mg/dL. When CFVR of participants with HDL-C ≥ 70 mg/dL was compared with participants with lower HDL (≥ 50 and < 70 mg/dL), CFVR was lower in the high HDL group (2.20 ± 0.52 vs. 2.65 ± 0.53, p = 0.007).

Conclusion: HDL-C levels ≥ 70 mg/dL may negatively impact coronary microcirculation.

Keywords: Coronary flow velocity reserve, Coronary microcirculation, High HDL-C

Received: July 11, 2025; Revised: July 11, 2025; Accepted: September 14, 2025; Prepublished online: June 2, 2012; Published: May 20, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Telci Caklili O, Betul Ozcan F, Cakmak R, Irgi T, Konal O, Caliskan M. Coronary Flow Velocity Reserve in Subjects with High HDL Cholesterol. Cor Vasa. 2026;68(2):161-165. doi: 10.33678/cor.2025.100.
Download citation

References

  1. Despre J pierre. HDL-cholesterol as a marker of coronary heart disease risk : the Quebec cardiovascular study. Atherosclerosis 2000;153:263-272. Go to original source... Go to PubMed...
  2. Wilson PWF, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham heart study. Arteriosclerosis 1988;8:737-741. Go to original source... Go to PubMed...
  3. Tall AR, Rader DJ. Trials and Tribulations of CETP Inhibitors. Circ Res 2018;122:106-112. Go to original source...
  4. Gibson CM, Duffy D, Korjian S, et al. Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction. N Engl J Med 2024;390:1560-1571. Go to original source... Go to PubMed...
  5. Madsen CM, Varbo A, Nordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality inmen and women: Two prospective cohort studies. Eur Heart J 2017;38:2478-2486. Go to original source... Go to PubMed...
  6. Hirata A, Sugiyama D, Watanabe M, et al. Association of extremely high levels of high-density lipoprotein cholesterol with cardiovascular mortality in a pooled analysis of 9 cohort studies including 43,407 individuals: The EPOCH-JAPAN study. J Clin Lipidol 2018;12:674.e5-684.e5. Go to original source... Go to PubMed...
  7. Takaeko Y, Matsui S, Kajikawa M, et al. Association of extremely high levels of high-density lipoprotein cholesterol with endothelial dysfunction in men. J Clin Lipidol 2019;13:664.e1-672.e1. Go to original source...
  8. Liu C, Dhindsa D, Almuwaqqat Z, et al. Very High High-Density Lipoprotein Cholesterol Levels and Cardiovascular Mortality. Am J Cardiol. 2022;167:43-53. Go to original source...
  9. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 2019;290:140-205. Go to original source... Go to PubMed...
  10. Erdogan D, Caliskan M, Gullu H, et al. Coronary flow reserve is impaired in patients with slow coronary flow. Atherosclerosis 2007;191:168-174. Go to original source...
  11. Djordjevic Dikic A, Tesic M, Boskovic N, et al. Prognostic Value of Preserved Coronary Flow Velocity Reserve by Noninvasive Transthoracic Doppler Echocardiography in Patients With Angiographically Intermediate Left Main Stenosis. J Am Soc Echocardiogr 2019;32:74-80. Go to original source...
  12. Van De Hoef TP, Siebes M, Spaan JAE, Piek JJ. Fundamentals in clinical coronary physiology: why coronary flow is more important than coronary pressure. Eur Heart J 2015;36:3312-3319. Go to original source... Go to PubMed...
  13. Erdogan D, Yildirim I, Ciftci O, Ozer I. Effects of normal blood pressure, prehypertension, and hypertension on coronary microvascular function. Circulation 2007;115:593-599. Go to original source... Go to PubMed...
  14. Kaul S, Coin B, Hedayiti A, et al. Rapid reversal of endothelial dysfunction in hypercholesterolemic apolipoprotein E-null mice by recombinant apolipoprotein A-I(Milano)-phospholipid complex. J Am Coll Cardiol 2004;44:1311-1319. Go to original source...
  15. Tardif JC. Emerging high-density lipoprotein infusion therapies: Fulfilling the promise of epidemiology? J Clin Lipidol 2010;4:399-404. Go to original source...
  16. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003;290:2292-2300. Go to original source...
  17. Nicholls SJ, Puri R, Ballantyne CM, et al. Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial. JAMA Cardiol 2018;3:806-814. Go to original source... Go to PubMed...
  18. Franczyk B, Rysz J, Ławiński J, Rysz-Górzyńska M, Gluba-Brzózka A. Is a high hdl-cholesterol level always beneficial? Biomedicines. 2021;9:1083. Go to original source...
  19. Barter PJ, Brewer HB, Chapman MJ, et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23:160-167. Go to original source... Go to PubMed...
  20. Schwartz GG, Olsson AG, Abt M, et al. Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. N Engl J Med 2012;367:2089-2099. Go to original source... Go to PubMed...
  21. Barter PJ, Caulfield M, Eriksson M, et al. Effects of Torcetrapib in Patients at High Risk for Coronary Events. N Engl J Med 2007;357:2109-2122. Go to original source... Go to PubMed...
  22. Boden WE, Probst-field JL, Anderson T, Chaitman BR. Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. N Engl J Med. 2011;365:2255-2267. Go to original source...
  23. Bowman L, Hopewell JC, Chen F, et al. The members of the writing committee. N Engl J Med. 2017;13:1217-1244.
  24. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111-188. Go to original source... Go to PubMed...
  25. Tsuda S, Shinohara M, Oshita T, et al. Novel mechanism of regulation of the 5-lipoxygenase/leukotriene B 4 pathway by high-density lipoprotein in macrophages. Sci Rep. 2017;7:12989.. Go to original source...
  26. Kontush A, Lindahl M, Lhomme M, et al. Structure of HDL: particle subclasses and molecular components. Handb Exp Pharmacol. 2015;224:3-51. Go to original source...
  27. Khera A V., Cuchel M, de la Llera-Moya M, et al. Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis. N Engl J Med 2011;364:127-135. Go to original source...
  28. Gomaraschi M, Ossoli A, Pozzi S, et al. eNOS activation by HDL is impaired in genetic CETP deficiency. PLoS One 2014;9:3-10. Go to original source... Go to PubMed...
  29. Van Eck M, Twisk J, Hoekstra M, et al. Differential effects of scavenger receptor BI deficiency on lipid metabolism in cells of the arterial wall and in the liver. J Biol Chem 2003;278:23699-23705. Go to original source... Go to PubMed...
  30. Zanoni P, Khetarpal SA, Larach DB, et al. Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science 2016;351:1166-1171. Go to original source... Go to PubMed...
  31. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, et al. Elevated HDL Cholesterol Is a Risk Factor for Ischemic Heart Disease in White Women When Caused by a Common Mutation in the Cholesteryl Ester Transfer Protein Gene. Circulation 2000;101:1907-1912. Go to original source... Go to PubMed...

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.